Repurposing an Antiviral Drug against SARS‐CoV‐2 Main Protease
Open Access
- 21 September 2021
- journal article
- review article
- Published by Wiley in Angewandte Chemie
- Vol. 60 (44), 23492-23494
- https://doi.org/10.1002/anie.202107481
Abstract
This article highlights recent pioneering work by Günther et al. towards the discovery of potential repurposed antiviral compounds (peptidomimetic and non-peptidic) against the SARS-CoV-2 main protease (Mpro). The antiviral activity of the most potent drugs is discussed along with their binding mode to Mpro as observed through X-ray crystallographic screening.Keywords
Funding Information
- Department of Atomic Energy, Government of India (RTI4007)
This publication has 17 references indexed in Scilit:
- Structure-based design of antiviral drug candidates targeting the SARS-CoV-2 main proteaseScience, 2020
- Boceprevir, GC-376, and calpain inhibitors II, XII inhibit SARS-CoV-2 viral replication by targeting the viral main proteaseCell Research, 2020
- The sprint to solve coronavirus protein structures — and disarm them with drugsNature, 2020
- A Trial of Lopinavir–Ritonavir in Adults Hospitalized with Severe Covid-19The New England Journal of Medicine, 2020
- Crystal structure of SARS-CoV-2 main protease provides a basis for design of improved α-ketoamide inhibitorsScience, 2020
- Structure of Mpro from SARS-CoV-2 and discovery of its inhibitorsNature, 2020
- Drug repurposing: progress, challenges and recommendationsNature Reviews Drug Discovery, 2018
- A multi-crystal method for extracting obscured crystallographic states from conventionally uninterpretable electron densityNature Communications, 2017
- Phase I Study of EKB-569, an Irreversible Inhibitor of the Epidermal Growth Factor Receptor, in Patients With Advanced Solid TumorsJournal of Clinical Oncology, 2006
- Inhibitory Effect of di- and Tripeptidyl Aldehydes on Calpains and CathepsinsJournal of Enzyme Inhibition, 1990